Core Viewpoint - Coeptis Therapeutics Holdings, Inc. has received shareholder approval for its merger with Z Squared Inc., which will result in Z Squared becoming a wholly owned subsidiary of Coeptis [1][2]. Company Overview - Coeptis is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [4]. - The company operates through its subsidiaries, including Coeptis Pharmaceuticals, GEAR Therapeutics, SNAP Biosciences, and Coeptis Technologies [4]. Therapeutic Portfolio - Coeptis's therapeutic portfolio includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy technology [5]. - The company is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and the Karolinska Institute [5]. Technology Division - Coeptis has established a Technology Division aimed at enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group [6]. Z Squared Overview - Z Squared is a digital infrastructure company focused on securing the Dogecoin and Litecoin networks through institutional-scale mining operations [8]. - Upon merger completion, Z Squared plans to deploy 9,800 ASIC miners across facilities in North Carolina, South Carolina, and Iowa, positioning itself as the largest publicly traded pure-play Dogecoin miner in the U.S. [8]. Operational Model - Z Squared emphasizes efficiency and risk management, converting mined assets to USD or stablecoins typically within 24 hours, aligning with a cash-flow-focused strategy [9]. - The company is led by a team with extensive expertise in cryptocurrency mining operations and infrastructure management [9].

CSG Systems International logo Coeptis Therapeutics Holdings Incorporated held its Annual and Special Meeting of Stockholders virtually, with Chief Executive Officer and Chairman Michael Mehalick presiding. The company noted the meeting was being recorded and outlined rules of conduct for participants using the webcast portal, including limitations on recording and a request that stockholders submit no more than one question. Mehalick introduced members of management and the board in attendance, includi ...

Summary of Coeptis Therapeutics Holdings Incorporated Annual and Special Meeting Company Overview - **Company Name**: Coeptis Therapeutics Holdings Incorporated - **Meeting Date**: January 30, 2026 - **Format**: Virtual meeting Key Points Discussed Meeting Structure - The meeting was called to order at 10:00 A.M. ET, with a quorum present [1] - The business portion was conducted first, followed by a Q&A session [3] Proposals Voted On 1. **Merger Proposal**: Approval of the issuance of terms of the merger with Z Squared Inc. as per the Agreement and Plan of Merger dated April 25, 2020 [5] 2. **Name Change Proposal**: Amending the certificate of incorporation to change the company's legal name from Coeptis Therapeutics Holdings, Inc. to Z Squared Inc. [6] 3. **Incentive Compensation Plan**: Approval of the company's 2025 incentive compensation plan [7] 4. **Board of Directors Proposal**: Election of directors effective until the next annual meeting [8] 5. **Option Exchange Proposal**: Approval of a one-time option event to reset the exercise price of outstanding underwater options [9] 6. **Ratification of Accounting Firm**: Ratification of the appointment of an independent registered public accounting firm [10] 7. **Executive Compensation Advisory Vote**: Non-binding advisory proposal on the compensation of named executive officers [10] 8. **Adjournment Proposal**: Proposal to adjourn the meeting if necessary [11] Voting Process - Polls were opened for stockholders to vote on the proposals, with instructions provided for submitting votes [2][4] Conclusion of Meeting - The meeting concluded with a note that all proposals were preliminarily approved, and the adjournment proposal was deemed unnecessary [11][12] Additional Important Information - The final results of the meeting will be reported in a current report on Form 8-K within four business days [12] - The meeting emphasized the importance of stockholder participation and thanked attendees for their contributions [11]

Core Viewpoint - Coeptis Therapeutics Holdings, Inc. has announced that its registration statement for a merger with Z Squared Inc. has been declared effective by the SEC, and it will begin mailing the definitive proxy statement/prospectus to stockholders ahead of the Stockholder Meeting scheduled for January 30, 2026 [1] Company Overview - Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [3] - The company operates through its subsidiaries, including Coeptis Pharmaceuticals, GEAR Therapeutics, SNAP Biosciences, and Coeptis Technologies [3] Therapeutic Portfolio - Coeptis's therapeutic portfolio includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy technology [4] - The company is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and the Karolinska Institute [4] Technology Division - Coeptis has established a Technology Division aimed at enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group [5] Z Squared Overview - Z Squared is focused on building a sustainable cryptocurrency mining operation, with 9,000 ASIC miners targeting Dogecoin and Litecoin, addressing market caps of $20 billion and $6 billion respectively [7] Stockholder Meeting - The Stockholder Meeting for the merger transaction will be held on January 30, 2026, with notices being mailed to stockholders of record as of January 2, 2026 [1]

Company Overview - Coeptis Therapeutics Holdings, Inc. is a next-generation technology and biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [3][4] - The company has a therapeutic portfolio that includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy technology [4] - Coeptis is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and the Karolinska Institute [4] Recent Developments - Coeptis has filed a registration statement on Form S-4 with the SEC related to a proposed merger agreement with Z Squared Inc. [1][2] - The Form S-4 includes a preliminary proxy statement/prospectus regarding the proposed transaction, which has not yet become effective [2] Technology Division - Coeptis has established a Technology Division aimed at enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group [5] Z Squared Overview - Z Squared Inc. is focused on digital asset compute mining, primarily generating Dogecoin (DOGE) and other digital assets like Litecoin, with a market cap of $20 billion [7]

Core Viewpoint - Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the mergers of Coeptis Therapeutics Holdings, Inc. and Pacific Premier Bancorp, Inc. [1][2] Group 1: Coeptis Therapeutics Holdings, Inc. - The investigation focuses on Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) regarding its merger with Z Squared Inc. [1] - Shareholders of Coeptis are encouraged to learn about their legal rights and options related to the merger [1] Group 2: Pacific Premier Bancorp, Inc. - Pacific Premier Bancorp, Inc. (NASDAQ: PPBI) is being investigated in connection with its sale to Columbia Banking System, Inc. [2] - The sale involves an exchange ratio of 0.9150 of a share of Columbia common stock for each Pacific share [2] - Shareholders of Pacific are urged to understand their rights and options concerning the transaction [2] Group 3: Legal Representation and Actions - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief on behalf of shareholders [3] - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [3] - Shareholders can contact the firm for free consultations regarding their legal rights and options [4]

Group 1 - Monteverde & Associates PC is investigating Coeptis Therapeutics Holdings, Inc. regarding its proposed merger with Z Squared Inc., where Z Squared shareholders will receive equity in Coeptis in exchange for 9,000 U.S. based dogecoin mining machines [1] - Monteverde & Associates PC has a successful track record in recovering millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1] - The firm operates from the Empire State Building in New York City and emphasizes its national class action securities litigation capabilities [2][3] Group 2 - The firm encourages shareholders with concerns about Coeptis Therapeutics to seek additional information free of charge [3] - Monteverde & Associates PC highlights its litigation experience, including cases that have reached the U.S. Supreme Court [2]

Core Viewpoint - Coeptis Therapeutics Holdings, Inc. and Z Squared Inc. have entered into a definitive merger agreement, resulting in Z Squared becoming a wholly-owned subsidiary of Coeptis, with a focus on Dogecoin mining and a planned spin-out of Coeptis' biopharmaceutical operations [1][5][10] Company Overview - Coeptis Therapeutics is a biopharmaceutical and technology company that develops innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [1][6] - Z Squared Inc. specializes in digital asset mining, primarily focusing on Dogecoin, which has a market capitalization exceeding $20 billion [2][10] Merger Details - The merger will involve a wholly-owned subsidiary of Coeptis merging with Z Squared, with Z Squared shareholders receiving equity in Coeptis in exchange for 9,000 U.S.-based Dogecoin mining machines [1] - The transaction is expected to close in the third quarter of 2025, pending regulatory approvals and shareholder consent [1] Leadership Changes - Post-merger, Z Squared executives will lead the combined entity, with David Halabu as CEO and Michelle Burke as COO [3][4] - Current Coeptis CEO Dave Mehalick will exit the Board of Directors upon closing [3] Strategic Focus - The combined company aims to create the largest publicly-traded entity in the U.S. focused on Dogecoin mining, targeting both retail and institutional investors [5] - Coeptis plans to maintain its biopharmaceutical operations separately after the merger, allowing continued involvement in both sectors [5]